HC Wainwright Issues Optimistic Outlook for COGT Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Analysts at HC Wainwright boosted their Q2 2025 EPS estimates for Cogent Biosciences in a note issued to investors on Tuesday, May 20th. HC Wainwright analyst R. Burns now anticipates that the technology company will post earnings per share of ($0.58) for the quarter, up from their previous forecast of ($0.66). HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Cogent Biosciences' Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.24) EPS and FY2026 earnings at ($2.09) EPS.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The technology company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.04.

COGT has been the subject of several other reports. Needham & Company LLC restated a "hold" rating on shares of Cogent Biosciences in a report on Wednesday, February 26th. Robert W. Baird decreased their price target on shares of Cogent Biosciences from $8.00 to $7.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Piper Sandler upgraded shares of Cogent Biosciences to a "strong-buy" rating in a report on Friday, March 7th. Wedbush reiterated a "neutral" rating and issued a $11.00 target price on shares of Cogent Biosciences in a research note on Tuesday, February 25th. Finally, Scotiabank started coverage on shares of Cogent Biosciences in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $17.00 target price for the company. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Cogent Biosciences has an average rating of "Moderate Buy" and an average price target of $14.00.

Cogent Biosciences Stock Performance

Shares of COGT stock traded up $0.13 during trading on Thursday, hitting $4.95. 482,578 shares of the company were exchanged, compared to its average volume of 1,260,084. The firm has a market capitalization of $563.02 million, a price-to-earnings ratio of -1.99 and a beta of 1.91. The business's 50-day simple moving average is $5.13 and its 200 day simple moving average is $7.22. Cogent Biosciences has a twelve month low of $3.72 and a twelve month high of $12.61.

Institutional Trading of Cogent Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of COGT. CWM LLC boosted its holdings in shares of Cogent Biosciences by 11,869.9% during the 1st quarter. CWM LLC now owns 8,738 shares of the technology company's stock worth $52,000 after buying an additional 8,665 shares during the period. Schonfeld Strategic Advisors LLC bought a new stake in shares of Cogent Biosciences during the 4th quarter worth $78,000. Hsbc Holdings PLC bought a new stake in shares of Cogent Biosciences during the 4th quarter worth $81,000. KLP Kapitalforvaltning AS bought a new stake in shares of Cogent Biosciences during the 4th quarter worth $88,000. Finally, E Fund Management Co. Ltd. bought a new stake in shares of Cogent Biosciences during the 4th quarter worth $89,000.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.